The French Cochlear Implant Registry (EPIIC): Perception and language results in infants with cochlear implantation under the age of 24 months.


Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 31 8 2020
medline: 9 9 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

Multi-centre study of the National French Registry (EPIIC) of patients with cochlear implants, focusing on infants who were operated-on under the age of 24 months between 2012 and 2016. A total of 615 profoundly deaf infants, who received cochlear implants (CIs) before their second birthday, were included in the registry by different CI centers. Epidemiological, surgical, speech therapy and school, follow-up data were included in the registry, 12, 24, 36 and 48 months thereafter. The following parameters were studied: type of implantation (uni- or bilateral), complications, cause of deafness, category of auditory perception (CAP), Open-set word recognition score (OSW), speech intelligibility rating, lexical comprehension with EVIP (Peabody), communication mode and type of schooling. Bilateral simultaneous CI (BiCI) and unilateral CI (UniCI) groups were compared. There were 744 implantations. The explantation-reimplantation rate, within the four-year follow-up, was just 3.6%. Mean implantation age was 16.0 months, and similar in the two groups (BiCI/UniCI). A total of 51% of children had their first implant between 12 and 18 months, and 15% before 12 months. Implantation was unilateral in 52% of cases. Fifty-six percent of the bilateral procedures were sequential, with a mean delay of 16.8 months for the second implantation. The cause of deafness was unknown in 52% of cases. Of the 48% (297/615) of attributed cases, 32% had clear genetic causes. The remaining deafness was due to cytomegalovirus (CMV, 8%), inner-ear malformation (5%) and meningitis (3%). The main complications were from infections (47%) and internal device failure (25%). Four years post-operation, 84% of the UniCI and 75% of BiCl groups had a CAP≥5, and 83% of UniCl and 100% BiCI had OSW≥80%. Furthermore 74% of UniCI and 77% of BiCI communicated orally and 85% of UniCI and 90% of BiCI integrated into mainstream schooling. The French Registry of cochlear implants (EPIIC) is the only such national registry in the world. Our analysis illustrates the immediate benefits of, either single or double, cochlear implantation for language, perception skills and schooling.

Identifiants

pubmed: 32863156
pii: S1879-7296(20)30176-9
doi: 10.1016/j.anorl.2020.07.010
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

S11-S18

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

N Loundon (N)

Department of Pediatric Otolaryngology, Hôpital Necker-Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France. Electronic address: natalie.loundon@aphp.fr.

F Simon (F)

Department of Pediatric Otolaryngology, Hôpital Necker-Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France.

K Aubry (K)

CHU de Limoges, Limoges, France.

P Bordure (P)

CHU de Nantes, Nantes, France.

A Bozorg-Grayeli (A)

CHU de Dijon, Dijon, France.

O Deguine (O)

CHU de Toulouse, Toulouse, France.

C Eyermann (C)

CHU de Strasbourg, Strasbourg, France.

V Franco-Vidal (V)

CHU de Bordeaux, Bordeaux, France.

B Godey (B)

CHU de Rennes, Rennes, France.

N Guevara (N)

CHU de Nice, Nice, France.

A Karkas (A)

CHU de St Etienne, Saint-Etienne, France.

N Klopp (N)

CHU d'Amiens, Amiens, France.

M Labrousse (M)

CHU de Reims, Reims, France.

J-P Lebreton (JP)

CHU de Poitiers, Poitiers, France.

Y Lerosey (Y)

CHU de Rouen, Rouen, France.

E Lescanne (E)

CHU de Tours, Tours, France.

R Marianowski (R)

CHU de Brest, Brest, France.

F Merklen (F)

CHU de Montpellier, Montpellier, France.

K Mezouaghi (K)

CH de La Réunion, La Réunion, France.

T Mom (T)

CHU de Clermont-Ferrand, Clermont-Ferrand, France.

S Moreau (S)

CHU de Caen, Caen, France.

I Mosnier (I)

Hôpital Pitié-Salpétrière, Paris, France.

N Noël-Petroff (N)

Hôpital Robert-Debré, Paris, France.

C Parietti-Winkler (C)

CHU de Nantes, Nantes, France.

P Piller (P)

CH de Nouméa, Nouméa, Nouvelle-Calédonie.

C Poncet (C)

Hôpital Rothschild, Paris, France.

E Radafy (E)

CH du Lamentin, Martinique, France.

S Roman (S)

CHU de Marseille, Marseille, France.

S Roux-Vaillard (S)

CHU d'Angers, Angers, France.

S Schmerber (S)

CHU de Grenoble, La Tronche, France.

L Tavernier (L)

CHU de Besançon, Besançon, France.

E Truy (E)

CHU de Lyon, Lyon, France.

C Vincent (C)

CHU de Lille, Lille, France.

A De Lamaze (A)

Department of Pediatric Otolaryngology, Hôpital Necker-Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH